Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibAssessing the barriers to image-guided drug delivery.Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionNurse-like cells promote CLL survival through LFA-3/CD2 interactions.Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds.Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.T cells in chronic lymphocytic leukemia: can they fight?Role of LFA-1 and ICAM-1 in Cancer.Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells.Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
P2860
Q26768154-6528A51F-41FA-4B31-944D-FF9A47E76E40Q27003955-C6DE9BCD-7F93-4559-9A46-1C59CD8C2F79Q27025812-E17165BD-425A-4C20-BD6E-3FA184C1C493Q30422169-3D2E0225-7865-4223-959C-167674652A53Q33621881-B8EF650A-2C25-4491-9A2A-7AA30FC52AF7Q34625543-3D164883-716A-4512-9FDD-4AF6E4A89A6EQ35836864-7F720DBB-5D09-4156-8A89-61EAF9133CD1Q35925086-8E43B97F-8A75-4F36-A960-7D23ADB43D9AQ36296595-2D201097-EF4A-4A2C-B9C3-A0A299FB3825Q36544769-765F8245-34A4-4B33-95DB-FDB764C2CD15Q36715966-4E7A7924-934B-4642-B021-0F447D6845CEQ37457945-A76CE632-F959-4F05-BBE7-3E8308874EF8Q37605306-FE7651D1-07DF-47C7-86AD-990017588271Q37628625-4A1DC277-486B-40C0-885F-7C2D9556B322Q38108353-D2BF069B-DBB2-4F6F-B142-D1EEFDE73105Q38231432-3FC69E7F-8E61-4BAD-B05E-71CFE771C2BFQ38445357-757F94F8-CBE1-46B4-9EAE-F815E32AA945Q38550810-DA3F57EB-C335-4B9E-9FD2-BD805464327BQ39136762-147F4A27-AD16-4D97-85AB-C7F65D7B36FAQ41592654-5051A9E5-9929-40FE-809E-7844584B7441Q42106541-3ABEFA86-FE14-4E1B-80EA-79324ACBA85DQ46011813-834781AB-191C-4375-A296-DF1B112F0259Q47096154-C2B0F94E-AEB7-40DA-9DC1-4931B1964042Q47106562-63538E6C-D301-43A0-AD41-9BF8950442A7Q48187234-E3C798FF-AEE2-4CD7-A721-08C6EC3A1E49Q50716088-545EA7C0-EE68-41F0-A60F-40676D9EB600Q51709036-2430A95B-FE78-4219-8F25-ABB1574AEB54Q52897863-7BA8BF9F-AF43-49C1-990C-40F6AA9A8302Q53152345-ABD6AFBB-EDEF-4285-AB1F-D1FC1A3D9A2DQ57174839-1A917F74-3550-4438-A519-34C147B553F3Q57807709-7E193D07-9F31-42F9-B20C-0A619D8D9141
P2860
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@ast
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@en
type
label
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@ast
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@en
prefLabel
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@ast
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@en
P2093
P2860
P1433
P1476
Chronic lymphocytic leukemia c ...... reversible with lenalidomide.
@en
P2093
John G Gribben
Lena Svensson
Nancy Hogg
Shahryar Kiaii
P2860
P304
P356
10.1182/BLOOD-2012-08-448332
P407
P577
2013-01-16T00:00:00Z